Evidence indicates that mitogen-activated protein kinase (MAPK) pathways play a crucial role in the neurobiology of the nervous system. In the present study, dopamine receptor-mediated regulation of extracellular signal-regulated kinases (ERKs) was examined in rats in which the nigrostriatal dopaminergic pathway was unilaterally lesioned by 6-hydroxydopamine (6-OHDA). Subcutaneous injections of the D 2 receptor agonist quinpirole significantly increased tyrosine-phosphorylated ERK1/2 in lesioned striatum, whereas the D 1 receptor agonist SKF38393 failed to activate ERKs. Quinpirole-induced phosphorylation of ERK1/2 was seen as early as 3 min and peaked at 15 min after the challenge. In parallel, striatal ERK kinase activity, measured by the in vitro kinase assay, was increased 2.5-fold on the lesioned side after the administration of quinpirole. Immunohistochemical examination of brain sections after quinpirole administration revealed significant increases in ERK1/2 immunostaining in perinuclear and intranuclear areas of striatal neurons. This increase was much more pronounced on the lesioned than the intact side. Furthermore, quinpirole-induced contralateral rotation was decreased by 48.7 and 50.7%, respectively, when the striatal ERK pathway was selectively inhibited by a single intrastriatal injection of the MAPK/ ERK kinase inhibitor PD098059 or after a continuous 7 d intrastriatal infusion of ERK1/2 antisense oligodeoxynucleotide. The results demonstrate, for the first time, that the ERK signaling pathway is activated in denervated striatum in response to stimulation of D 2 dopamine receptors and that the resulting imbalance in striatal ERK activity contributes, at least in part, to neuronal plasticity that underlies D 2 dopamine receptor-mediated contralateral rotation in unilateral 6-OHDA denervated rats.
Mitogen-activated protein kinases (MAPKs) are a group of intracellular protein kinases, including extracellular signalregulated kinase (ERK), p38 MAPK and c-Jun amino-terminal kinase/stress-activated protein kinase (JNK/SAPK). The first and best characterized MAPK cascade consists of Ras, Raf, MEK1/2, and ERK1/2 and has been demonstrated to be involved in regulation of cell proliferation and differentiation (Boulton et al., 1990 (Boulton et al., , 1991 Blumer and Johnson, 1994; Sale et al., 1995; Robinson and Cobb, 1997) . Growth factors, by acting on intrinsic receptor tyrosine kinases (RTK), are primary activators of the MAPK pathway (Schlessinger and Ullrich, 1992; Seger and Kerbs, 1995) . Accumulated evidence has also demonstrated that stimulation of G-protein-coupled receptors (GPCRs) activates the MAPK pathways via ras-dependent (Crespo et al., 1994; van Biesen et al., 1995; Touhara et al., 1995; Wan et al., 1996; Della Rocca et al., 1997; Luttrell et al., 1997) or ras-independent mechanisms (Pace et al., 1995; Takahashi et al., 1997) . Similar to growth factors, GPCR-mediated activation of the MAPK pathway has also been linked to cell proliferation and tissue hypertrophy. For example, activation of MAPK by ␣ 1 adrenoceptors is implicated in vascular smooth muscle and cardiac hypertrophy (Bogoyevitch et al., 1996; Glennon et al., 1996; Hu et al., 1996; Ramirez et al., 1997) . However, the abundant expression of MAPKs in postmitotic neuronal tissue implies that these pathways mediate functions other than those involved in regulating cell growth (Boulton et al., 1991; Fiore et al., 1993) . Indeed, some studies have shown that the MAPK signal pathway is involved in regulating expression of tyrosine hydroxylase, the rate-limited enzyme in the biosynthesis of catecholamines (Gizang-Ginsberg and Ziff, 1990; Haycock et al., 1992; Lewis et al., 1994; Rabinovsky et al., 1995) and may contribute to the increase in tyrosine hydroxylase that develops during chronic treatment with cocaine or morphine (Berhow et al., 1996) . Activation of this pathway has recently been found to be related to long-term potentiation Sweatt, 1996, 1997; Impey et al., 1998) , long-term facilitation (Martin et al., 1997) , and classical conditioning (Crow et al., 1998) , and is an essential step for memory formation (Skoulakis and Davis, 1996; Brambilla et al., 1997; Silva et al., 1997; Atkins et al., 1998) . In the present study, we examined, in vivo, striatal D 2 dopamine receptor-mediated regulation of ERK signaling in 6-hydroxydopamine (6-OHDA)-lesioned rats in which the striatal D 2 dopamine receptors are upregulated and sensitized. Our results demonstrate that in vivo stimulation of D 2 dopamine receptors activates the ERK cascade in the denervated striatum and that this signaling pathway plays an important role in mediating the hypersensitive locomotor response initiated by D 2 dopamine receptor stimulation.
MATERIALS AND METHODS
Animal surger y and behavioral assessment. Male Sprague Dawley rats, 220 -250 gm, were purchased from Harlan (Indianapolis, I N). Animals were anesthetized with intraperitoneal injections of 50 mg / kg sodium pentobarbital and received a single stereotactic injection of 8 g of 6-OH DA hydrochloride in 4 l of artificial C SF with 0.05% ascorbic acid into the medial forebrain bundle using the following coordinates: anteroposterior (AP), Ϫ2.5 mm; lateral (L), ϩ2.0 mm; and dorsoventral (DV), Ϫ8.5 mm using bregma as the starting point. To limit damage to adrenergic neurons, 25 mg / kg desipramine hydrochloride was administered intraperitoneally 30 min before 6-OH DA. The success of the lesion was assessed by monitoring contralateral rotations in response to a single 0.2 mg / kg apomorphine hydrochloride challenge dose administrated subcutaneously 3 weeks after surgery. For assessing rotational behavior, lesioned rats were placed in 50-cm-diameter bowls and allowed to acclimate to the environment for 30 min before the injection of apomorphine. Animals demonstrating fewer than 20 rotations per 5 min were excluded from f urther experiments. The selected animals exhibited Ͼ90% depletion of striatal dopamine levels on the lesioned side as measured by HPLC. To assess responses of dopamine receptors, the specific D 1 receptor agonist SK F38393 (5 mg / kg, s.c.) or the D 2 receptor agonist quinpirole (1 mg / kg, s.c.) were used.
Antisense oligodeoxynucleotide treatment. Antisense oligodeoxynucleotide (ODN) (5Ј-GCCGCCGCCGCCGCCAT-3Ј) and sense control ODN (5Ј-ATGGCGGCGGCGGCGGC -3Ј) directed against the initiation translation site of rat ERK1/2 (Sale et al., 1995) and phosphorothioated at the 5Ј-and 3Ј-ends were synthesized by the Midland C ertified Reagent Company (Midland, TX). The ODNs were dissolved in artificial C SF and delivered via osmotic minipumps connected to Alzet (Palo Alto, CA) brain inf usion cannulas, and directed into the lateral dorsal striatum on the lesioned side using the following coordinates: AP, Ϫ0.5 mm; L, ϩ5 mm; and DV, Ϫ5 mm. The osmotic pumps were placed beneath the skin of the dorsal neck, and the ODNs were continuously inf used at a rate of 1 l / hr (10 ng /d). Contralateral rotations in response to a subcutaneous injection of 1 mg / kg quinpirole was assessed after 7 d of continuous ODN inf usion.
PD098059 treatment. PD098059 (2Ј-amino-3Ј-methoxyflavone; Biomol, Plymouth Meeting, PA) was dissolved in dimethylsulfoxide (Me 2 SO) and diluted with PBS to give the desired drug concentration in 0.1% Me 2 SO. Rats were anesthetized with inhaled halothane, and single injections of 0.4 -1.6 g PD098059 or vehicle were directed into the lateral dorsal striatum ipsilateral to the 6-OH DA lesion at the coordinates: AP, Ϫ0.5 mm; L, ϩ5 mm; and DV, Ϫ5 mm. The number of rotations in response to a subcutaneous injection of 1 mg / kg quinpirole, administered 2 hr after the intrastriatal injection of PD098059, was counted for 5 min.
Lysate preparation. Striata obtained from both sides of the brain were sonicated in 2 ml of ice-cold lysis buffer containing (in mM): 50 Tris-HC l, pH 7.4, 150 NaC l, 1 EGTA, 10 NaF, 1 Na 3 VO 4 , 40 ␤-glycerophosphate, 1 sodium pyrophosphate, 1 phenylmethylsulfonyl fluoride (PMSF), 10 g /ml aprotinin, 10 g /ml leupeptin, and 1% Nonidet P-40. The homogenates were allowed to stand on ice for 30 min and centrif uged at 12,000 ϫ g for 15 min at 4°C. The protein content in the supernatants was determined by the Bradford assay using bovine serum albumin as standard. The lysates were stored at Ϫ80°C until use.
Immunoprecipitation and immunoblotting. One milligram of striatal lysates were incubated overnight at 4°C with 10 l agarose-conjugated anti-phosphotyrosine monoclonal antibody (4G10; Upstate Biotechnology, Lake Placid, N Y). Immunoprecipitates were washed three times with lysis buffer and resuspended in 40 l of sample buffer containing 62.5 mM Tris-HC l, pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.1% bromophenol blue. Striatal lysate supernatant proteins or the immunoprecipitates of phosphotyrosine-containing proteins were size-separated on 12% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were incubated with 1:1000 dilutions of anti-pan ERK antibody (Transduction Laboratories, Lexington, K Y), or specific anti-ERK1/2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 hr followed by 1 hr incubation with 1:10,000 dilution of anti-rabbit secondary antibody. The signals were visualized with enhanced chemiluminescence (ECL) Supersignal Western Blot Detection System (Pierce, Rockford, IL) and exposed to x-ray film. The specific bands were quantified by soft-laser densitometry (Biomed Instruments, Fullerton, CA).
In vitro ER K k inase assay. The assay for ERK phosphotransferase activity was performed as described previously (Z hen et al., 1998a ) using myelin basic protein (MBP; 0.25 mg /ml) as substrate. The immunoprecipitates obtained with anti-ERK1/2 antibody were washed and suspended in buffer containing (in mM): 25 H EPES, pH 7.5, 10 MgC l 2 , 1 DTT, and 0.2 Na 3 VO 4 . The suspended immunoprecipitates were incubated with 10 M [␥-32 P] ATP (3000 C i /mmol; DuPont N EN, Boston, M A) at 30°C for 20 min. The total reaction volume was 40 l. The reactions were stopped with 40 l of a twofold concentrated sample buffer. T wenty microliters of each reaction mixture were subjected to 12% SDS-PAGE. The gels were dried and the radioactivity incorporated into MBP was detected by autoradiography or by scintillation counting.
Immunohistochemical localization of ER K . Whole rat brains were rapidly removed and frozen in dry ice powder. Cryosections of 10 m thickness were cut and stored at Ϫ70°C until use. The sections were returned to room temperature with the aid of cool air generated by a hair dryer. The sections were immersed into ice-cold fixative solution containing 1% paraformaldehyde and 0.2 M lysine, pH 7.4, for 20 min and briefly rinsed with PBS and incubated for 1 hr at room temperature in PBS containing 4% BSA and 0.1% Triton X-100. The sections were incubated overnight with a 1:250 dilution of anti-ERK1/2 polyclonal antibody (R2; Upstate Biotechnology, Lake Placid, N Y) and with a 1:50 dilution of anti-M AP-2 monoclonal antibody (a gift of Dr. I. Fisher, MC P Hahnemann University). Sections were rinsed in PBS with 0.1% Triton X-100 and incubated for 1 hr with purified fluorescein-conjugated goat anti-rabbit IgG and purified Texas Red-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA) in PBS with Triton X-100. The sections were then rinsed gently in PBS with Triton X-100, mounted onto slides with aqueous mounting media (Fisher Scientific, Pittsburgh, PA), and examined on a Leica (Nussloch, Germany) microscope with a CCD camera connected to a computer, using ultraviolet with 568 or 488 nm excitation frequency filters. Adjacent sections from each animal brain were processed without primary or secondary antibody and used as negative control in each experiment.
Radioligand binding studies. D 2 dopamine receptor binding was assessed with the selective D 2 dopamine receptor antagonist [
3 H]raclopride. Briefly, saturation binding was performed at 37°C for 30 min in reaction mixture containing (in mM): 50 Tris-HC l buffer, pH 7.4, 120 NaCl, 5 KCl, 2 CaCl 2 , 1 MgC l 2 , and 0.125-16 nM [
3 H]raclopride, with 100 g of striatal membranes. The reaction was terminated by vacuum filtration through Whatsman GF/ B filter followed by washing with cold 50 mM Tris-HC l buffer, pH 7.4. Nonspecific binding was defined by binding in the presence of 10 M spiperone. The radioactivity in the filters was measured by liquid scintillation spectrometry. Receptor density and affinity were determined by Scatchard analysis.
RESULTS

The expression and localization of ERKs in striatal neurons and the effect of dopamine receptor stimulation
Striatal ERK expression was measured in tissue lysates by immunoblot analysis using the anti-pan ERK antibody. As shown in Figure 1 , two isoforms of ERK, ERK1 (44 kDa) and ERK2 (42 kDa), were detected. ERK2 was the dominant form found in striatum of rat brain. An additional 54 kDa band was also found in the immunoblot. Similar expression patterns and levels of ERKs were found in the control and denervated striata. Stimulation of D 2 or D 1 dopamine receptors by injections of the respective selective dopamine receptor agonists quinpirole or SKF38393 did not alter the expression levels of striatal ERK proteins ( Fig. 1 ).
Immunohistochemical staining with anti-ERK1/2 antibody revealed ERK immunoreactivity in striatal midsize neurons identified by staining with an MAP-2 antibody, as well as in glial cells (Fig. 2a) . Neuronal ERK1/2 was readily detectable on the cell surface as well as in dendritic processes, whereas glial ERK was widely distributed throughout the cell cytoplasm. Subcellular localization of neuronal ERK did not exhibit a great deal of colocalization with the MAP-2 signal (Fig. 2b,c,e) . Few striatal MAP-2-positive cells exhibited ERK immunostaining perinuclearly.
Selective activation of striatal ERK pathway by D 2 dopamine receptor stimulation
Activation of the ERK pathway yielded increases in tyrosinephosphorylated ERKs. The phosphorylated ERKs were determined by immunoblotting with anti-phospho-ERK1/2 antibody or by first immunoprecipitating phosphotyrosine-containing proteins using an anti-phosphotyrosine antibody followed by immunoblotting with anti-ERK1/2 antibody (ERK2). As shown in Figure 3A , no difference in phosphorylated ERK1/2 was found between striata obtained from control and lesioned sides of unilaterally 6-OHDA-lesioned rats. However, an increase in phosphorylated ERK1/2 was found on the lesioned side 10 min after a subcutaneous administration of the dopamine receptor agonist apomorphine (0.2 mg/kg) or the specific D 2 dopamine receptor agonist quinpirole (1 mg/kg). In contrast, the D 1 dopamine receptor agonist SKF38393 (5 mg/kg) did not alter the level of phosphorylated ERK1/2. The specificity of the response was further tested with dopamine receptor antagonists. As shown in Figure 4 , pretreatment with the selective D 2 dopamine receptor antagonist spiperone at a dose (2 mg/kg, i.p.) that totally blocked quinpirole-mediated contralateral rotation, abolished quinpiroleinduced increases in phosphorylated ERK in the denervated striatum. However, the effects of quinpirole were not affected by pretreatment with the selective D 1 dopamine receptor antagonist SCH23390 (0.1 mg/kg, i.p.).
The time course for D 2 dopamine receptor-mediated increases in phosphorylated ERKs was assessed in striata obtained from rats 3, 8, 15, or 30 min after a subcutaneous challenge dose of 1 mg/kg quinpirole. Phosphorylated ERK2 was increased on the lesioned side 3 min after the injection of quinpirole. The increase in phosphorylated ERK reached maximum at 15 min and returned to control levels 30 min after quinpirole administration (Fig. 5) . On the control side, no significant change in striatal phosphorylated ERK was observed after the quinpirole challenge.
To test whether the quinpirole-induced increases in phosphor- Figure 1 . Effects of 6-OHDA lesion and dopamine receptor stimulation on striatal ERK expression. Unilateral 6-OHDA-lesioned rats were injected subcutaneously with saline (10 min), apomorphine (0.2 mg/kg, 10 min), quinpirole (1 mg/kg, 10 min), or SKF38393 (5 mg/kg, 15 min). Striata from both hemispheres were removed and lysed, and 20 g of lysates were subjected to SDS-PAGE followed by immunoblotting. The blots were incubated with a 1:1000 dilution of pan-ERK antibody. Immunoreactivity was detected by ECL. A typical blot and summary data (mean Ϯ SEM) obtained from densitometric scans of blots of four independent experiments in relative density units are shown. ylated ERK levels are accompanied by a change in ERK activity, striatal ERK activity was measured in tissues obtained from quinpirole-treated (1 mg/kg, s.c.) animals. Whereas comparable basal ERK activities were found in control and lesioned striata, quinpirole challenge increased ERK activity 2.5-fold on the lesioned but not on the control side of unilateral 6-OHDA-lesioned rats (Fig. 3B) .
Dopamine receptor-mediated regulation of striatal ERKs was further examined immunohistologically in animals treated with dopamine receptor agonists. No noticeable differences in cellular and subcellular ERK distributions were found between striata taken from control and lesioned sides after injections of saline (Fig. 2e,f ) or 5 mg/kg SKF38393 (Fig. 2g,h ). In contrast, 1 mg/kg quinpirole induced small increases in cytosol and cell surface ERK immunostaining in striatal MAP-2-positive cells on the intact side (Fig. 2i) . In denervated striatal neurons, quinpirole dramatically increased ERK immunostaining in perinuclear and nuclear regions of neurons. This subcellular ERK redistribution resulted in reduced overlap between ERK and MAP-2 staining (Fig. 2j ). The observations demonstrate that D 2 dopamine receptor stimulation elicits a redistribution of ERK from cell surface regions to perinuclear and nuclear regions of neurons and that this effect is more pronounced in striata on the lesioned side of unilateral 6-OHDA-injected rats.
Dependence of D 2 dopamine receptor-mediated rotation in unilateral 6-OHDA-lesioned rats on activation of striatal ERK pathway Dopamine receptor agonist-mediated contralateral rotation in unilateral 6-OHDA-lesioned rats has been previously demon- Figure 3 . Phosphorylation and activity of ERK1/2 in striatal membranes. Unilateral 6-OHDA-lesioned rats were injected subcutaneously with saline (10 min), quinpirole (1 mg/kg, 10 min), apomorphine (0.2 mg/kg, 10 min), or SKF38393 (5 mg/kg, 15 min). Striata from control ( C) and lesioned ( L) hemispheres were removed and lysed. For assessing ERK phosphorylation, 20 g of lysates were subjected to SDS-PAGE followed by immunoblotting. The blots were incubated overnight with a 1:1000 dilution of anti-phospho-MAPK (ERK1/2) antibody (New England Biolabs, Beverly, MA), and immunoreactivity was detected by ECL. A typical blot and summary of the results, in relative density units, obtained from densitometric scans of blots of five independent experiments are shown ( A). For measuring ERK activity, 400 g of lysates were immunoprecipitated with anti-ERK1/2 antibody, and activity was determined in the immunoprecipitates by measuring the phosphorylation of MBP in the presence of [␥- 32 P] ATP. The data obtained from four independent experiments are presented as mean Ϯ SEM ( B). *p Ͻ 0.05 and *p Ͻ 0.01 compared to intact control side by the paired t test. Figure 4 . Effect of dopaminergic antagonists on quinpirole-induced contralateral rotation and increases in striatal phosphorylated ERK1/2. Unilateral 6-OHDA-lesioned rats were injected intraperitoneally with vehicle, 2 mg/kg spiperone, or 0.1 mg/kg SCH23390, 30 min before a subcutaneous administration of 1 mg/kg quinpirole. The rotational behavior in response to quinpirole was assessed for a 5 min period, 5-10 min after the quinpirole injection. Responses to quinpirole administration after antagonist were compared to responses to quinpirole obtained before treatment with the dopaminergic antagonists. The results are presented as percent Ϯ SD of rotations obtained after dopaminergic antagonist treatment to that noted before the treatment in three animals per group ( A). **p Ͻ 0.01 compared to vehicle-treated group (ANOVA followed by Newman-Keuls test). Immediately after the behavioral test, striata from control ( C) and lesioned ( L) sides were removed, and 20 g of lysates were size-fractionated on SDS-PAGE followed by immunoblotting. The blots were incubated with a 1:1000 dilution of anti-phospho-MAPK (ERK1/2) antibody, and immunoreactivity was detected by ECL. A representative blot is shown ( B). The experiment was repeated three times, and similar results were obtained. strated in numerous laboratories to be a function of striatal dopamine receptor supersensitivity that develops after denervation of dopaminergic input to the striatum on the lesioned side. To test whether the ERK pathway plays a role in mediating dopamine receptor-stimulated rotational behavior, quinpiroleinduced contralateral rotation was determined after inhibition of the striatal ERK1/2 signaling cascade, ipsilateral to the lesion, with a direct intrastriatal injection of the MAPK/ERK kinase (MEK) inhibitor PD098059 (Alessi et al., 1995) . The injection of PD098059 dose-dependently inhibited the increase in striatal ERK activity that was produced by injections of quinpirole. ERK activation was inhibited by Ͼ80% at a dose of 1.6 g PD098059 (Fig. 6 A) . Correspondingly, quinpirole-induced rotational behavior, tested 2 hr after the administration of PD098059, was dosedependently inhibited by the inhibitor. Inhibition of 48.7% of quinpirole-induced rotations was achieved after the injection of 1.6 g PD098059 (Fig. 6 B) . In contrast, the contralateral rotation that was produced by the D 1 dopamine receptor agonist SKF38393 (5 mg/kg) was not altered by the intrastriatal injection of 1.6 g PD098059 (63 Ϯ 9 rotations/5 min vs 69 Ϯ 7 rotations/5 min; n ϭ 4).
In an attempt to further test the role of ERK in the expression of D 2 dopamine receptor supersensitivity that follows denervation of dopaminergic neuronal input to striatum, an antisense approach was used to specifically target the ERK1/2 isoforms in striatum. After a 7 d intrastriatal infusion of 10 ng/d of ERK1/2 antisense ODN ipsilateral to the 6-OHDA injection, the level of phosphorylated ERK that was induced by quinpirole was reduced by Ͼ70% (Fig. 7A) ; the same antisense ODN treatment resulted in a 22% decrease in expression of striatal ERKs on the denervated side when compared to the control side (Fig. 7B) . Neither ERK expression level nor quinpirole-mediated elevation in phosphorylated ERK were altered by intrastriatal treatment with the control sense ODN (Fig. 7A,B) . Correspondingly, quinpiroleinduced contralateral rotation was inhibited by 50.7% after intrastriatal infusion with the ERK1/2 antisense ODN. Intrastriatal infusion of the sense ODN did not affect quinpirole-induced rotation (Fig. 7C) .
The above treatments with PD098059 or ERK antisense ODN did not affect D 2 dopamine receptor binding density (B max ) (vehicle, 176 Ϯ 11 fmol/mg; PD098059, 173 Ϯ 4 fmol/mg; ERK Figure 5 . Time-dependent effect of quinpirole on striatal ERK2 phosphorylation. Unilateral 6-OHDA-lesioned rats received subcutaneous injections of saline or 1 mg/kg quinpirole and striata from control ( C), and lesioned ( L) hemispheres were removed after 3, 8, 15, or 30 min. The tissues were lysed, and 400 g of lysate proteins were used to immunoprecipitate phosphotyrosine-containing proteins with anti-phosphotyrosine antibody. The immunoprecipitated proteins were separated on SDS-PAGE, proteins were transferred to nitrocellulose membranes, and the blots were incubated with anti-ERK1/2 antibody. Immunoreactivity was detected by ECL. A typical blot and summary data (mean Ϯ SEM) obtained from densitometric scans of blots of four independent experiments in relative density units are shown. *p Ͻ 0.05 and **p Ͻ 0.01 compared to intact control side by the paired t test. Figure 6 . Effects of PD098059 on quinpirole-stimulated striatal ERK activity and rotational behavior. Under halothane anesthesia, unilateral 6-OHDA-lesioned rats received an intrastriatal injection of vehicle or PD098059 (PD) (0.4, 0.8, or 1.6 g) ipsilateral to the 6-OHDA lesion. Rats were injected subcutaneously with 1 mg/kg quinpirole (QP) 2 hr after PD injection, and rotational behavior was assessed for a 5 min period, 5-10 min after QP. Striata from control ( C) and lesioned ( L) hemispheres were removed after 10 min, lysed, and 400 g of lysates were immunoprecipitated with ERK1/2 antibody. ERK activity was determined by measuring the phosphorylation of MBP in the presence of [␥- 32 P]ATP, and proteins were separated on SDS-PAGE. The gels were dried, and the radioactivity incorporated into MBP was assessed by autoradiography. The ratios of radioactivity on the lesioned over the control sides were calculated from the densitometric assessment of the autoradiograms. A representative autoradiogram and summary data from three to four independent experiments are shown ( A). The behavioral response to QP after administration of PD was compared to the number of rotations elicited by QP in a test performed 4 d previously. The results obtained from three to four individual experiments are presented as percent Ϯ SEM of change in response to PD treatment ( B). *p Ͻ 0.05 and **p Ͻ 0.01 compared to the vehicle-treated group in the absence of quinpirole. ϩp Ͻ 0.05 and ϩϩp Ͻ 0.01 compared to vehicle-treated group in the presence of quinpirole (ANOVA followed by Newman-Keuls test).
antisense, 170 Ϯ 20 fmol/mg) or binding affinity (K d ) (6.1 Ϯ 0.6 nM; 6.0 Ϯ 0.5 nM; 5.8 Ϯ 0.5 nM), as determined by the assessment of specific D 2 dopamine receptor binding using the selective D 2 dopamine receptor antagonist [ 3 H]raclopride.
DISCUSSION
The present data demonstrate that in vivo stimulation of D 2 dopamine receptors activates the ERK signaling pathway in striata in which the dopaminergic input has been denervated via a unilateral injection of 6-OHDA. Moreover, activation of the ERK cascade in the striatum is necessary for the expression of locomotor hyperactivity that underlies D 2 dopamine receptor-mediated rotational behavior in unilateral 6-OHDA denervated rats. Activation of striatal ERK signaling by D 2 dopamine receptors was evident by the fact that acute challenge with the selective D 2 dopamine receptor agonist quinpirole increased tyrosinephosphorylated ERK1/2 and ERK activity in denervated striata. The increases in phosphorylated ERK1/2 and in ERK activity were not accompanied by an apparent change in ERK protein expression, implying that D 2 dopamine receptor stimulation activates this MAPK pathway. Furthermore, immunohistochemical analysis revealed that stimulation of D 2 dopamine receptors increased ERK immunoreactivity in nuclear and perinuclear areas of striatal medium-size neurons on the denervated side. The results also indicate that stimulation of D 2 dopamine receptor results in a translocation of cellular ERK1/2 into nuclei of striatal neurons. These results are the first to demonstrate that stimulation of D 2 dopamine receptors leads to the activation of the ERK pathway in brain neurons and are consistent with previous studies obtained in cultured cells overexpressing D 2 dopamine receptors (Lajiness et al., 1993; Yan et al., 1997) . This action appears to be specific for the D 2 receptor because it is selectively inhibited by a D 2 but not by a D 1 dopamine receptor antagonist, and stimulation of D 1 dopamine receptors did not influence the ERK signaling pathway assessed either by tyrosine-phosphorylated ERK levels or intracellular redistribution of ERK1/2 in striatal neurons. Nevertheless, stimulation of D 1 dopamine receptors were previously shown to inhibit PDGF-stimulated MAPK activity in vascular smooth muscle cells (Yasunari et al., 1997) , and recent studies in our laboratory have shown that stimulation of D 1 dopamine receptors activate the p38 MAPK and JNK pathways via a PKA-dependent mechanism in SK-N-MC human neuroblastoma cells (Zhen et al., 1998a) .
The signal transduction pathway for GPCR-mediated activation of MAPKs is less well defined than that for the growth factor receptors. It appears that GPCRs may be linked to MAPKs via 4 precipitates were subjected to SDS-PAGE, blotted with ERK1/2 antibody, and ERK immunoreactivity was detected by ECL. A typical blot and summary data (mean Ϯ SEM) obtained from the densitometric scans of four to six independent experiments in relative density units are shown ( A). To assess ERK expression, 20 g of striatal lysates were subjected to SDS-PAGE followed by immunoblotting with the pan-ERK antibody, and immunoreactivity was detected by ECL. A typical blot and summary data (mean Ϯ SEM) obtained from densitometric scans of four to six independent experiments in relative density units are shown ( B) . The behavioral response to quinpirole after administration of ODNs were compared to the responses to quinpirole obtained before treatment with the respective ODNs. The results are presented as the percent Ϯ SEM of rotations obtained after ODN treatment to that noted before the treatment in six to eight individual experiments ( C). *p Ͻ 0.05 and **p Ͻ 0.01 compared to intact control side by the paired t test. ϩp Ͻ 0.05 compared to vehicletreated group (ANOVA followed by Newman-Keuls test). Figure 7 . Effects of ERK1/2 antisense ODN treatment on quinpiroleinduced striatal ERK phosphorylation, expression, and rotational behavior. Under sodium pentobarbital anesthesia, a cannula connected to an Alzet osmotic minipump was stereotactically placed into the dorsal lateral striatum on the 6-OHDA-lesioned side. Vehicle ( V ), sense ODN ( S), or antisense (AS) ODNs were continuously delivered at 1 l/hr (10 ng/d for the ODNs) for 7 d. Rats were then challenged with a subcutaneous injection of 1 mg/kg quinpirole, and the rotational response was assessed for a 5 min period, 5-10 min after the quinpirole injection. Striata from control ( C) and lesioned ( L) sides were removed 10 min after quinpirole challenge. To assess ERK phopshorylation, 400 g of striatal lysates were immunoprecipitated with anti-phosphotyrosine antibody. The immuno-different mechanisms, depending on the specific G-protein subtype with which the receptor interacts (Faure et al., 1994; Crespo et al., 1995; Hanford and Glembotski, 1996; Xing and Insel, 1996; Yu et al., 1996; Pende et al., 1997) . The linkage of G i -proteincoupled receptors to MAPKs is mediated via the ␤␥ dimer of G-proteins that is released by the dissociation of the trimeric G-protein after receptor stimulation (Crespo et al., 1994; Koch et al., 1994; van Biesen et al., 1995; Luttrell et al., 1997) . This signaling pathway has been demonstrated for many G i -coupled receptors, including ␣ 2 adrenoceptor and 5-HT 1A serotonin receptor (Flordellis et al., 1995; Cowen et al., 1996; Garnovskaya et al., 1996) . D 2 dopamine receptors belong to the G i -proteincoupled receptor family and have been shown to inhibit adenylyl cyclase activity (Sokoloff and Schwartz, 1995) . The molecular signaling components that link the D 2 dopamine receptor to ERKs are yet to be determined. Recent studies performed in SK-N-MC human neuroblastoma cells and in MN9D cells that express D 4 dopamine receptors have demonstrated that the D 4 dopamine receptor-mediated activation of ERK signaling requires Src and SHC-Grb2 for interaction with a pertussis toxinsensitive G-protein (Zhen et al., 1998b) . It remains to be demonstrated whether D 2 dopamine receptors share the same pathway as D 4 dopamine receptors, both of which belong to the G i -linked D 2 -like dopamine receptor family.
The nigrostriatal dopaminergic pathway is a major brain dopamine-containing neuronal projection. Chronic interruption of this pathway or depletion of dopamine mimics the pathogenesis of Parkinson's disease and results in sensitization of locomotor responses to striatal D 1 and D 2 dopamine receptors in rodents (Arnt and Hyttel, 1984; Hu et al., 1990) . Increased D 1 dopamine receptor-G-protein coupling rather than altered D 1 receptor expression appears to underlie the sensitized response to D 1 dopamine receptor stimulation (Butkerait et al., 1994; Cai et al., 1998) . D 1 dopamine receptor-mediated cAMP-dependent activation of protein kinase A has been suggested to mediate the development of altered motor responses during chronic levodopa treatment (Oh et al., 1997) . On the other hand, the mechanism that leads to the development of supersensitivity of D 2 dopamine receptor-mediated responses is thought to be related to an increase in expression of D 2 dopamine receptors (Creese et al., 1977; Norman et al., 1987; Savasta et al., 1987; Qin et al., 1994) as well as enhanced D 2 receptor-G i -protein coupling (Rubinstein et al., 1990; Butkerait et al., 1994; Marcotte et al., 1994; Cai et al., 1998) . However, the intracellular signaling pathway that underlies hypersensitization of D 2 dopamine receptor-mediated locomotion was not previously determined. The present data demonstrate high ERK expression levels in striatal medium-size neurons that are involved in initiation and modulation of locomotor behavior (Kitai, 1981; Gerfen, 1995) . In vivo stimulation of D 2 dopamine receptors elicited contralateral rotation as well as activation of striatal ERK pathway in unilateral 6-OHDA-lesioned rats. More interestingly, D 2 dopamine receptor-mediated activation of ERKs was predominantly noted in striata ipsilateral to the 6-OHDA lesion, thus resulting in an imbalance in ERK signaling between the two sides of the brain. The predominant receptormediated activation of the ERK pathway in the denervated striatum appears to be a consequence of D 2 dopamine receptor upregulation and enhanced D 2 dopamine receptor-G-protein coupling that result in increased transmembrane signaling and ultimately enhanced intracellular signaling. Alternatively, this asymmetry in the activation of ERK may be mediated by the recruitment of the ERK signaling pathway during the development of dopaminergic supersensitivity. Furthermore, the phosphorylation and activation of striatal ERKs preceded the initiation of rotational behavior, and interference with this cascade either via striatal MEK inhibition or with ERK antisense ODN markedly inhibited quinpirole-elicited contralateral rotation. These data, therefore, indicate that enhanced striatal D 2 dopamine receptor-activated ERK signaling underlies the supersensitivity that ultimately results in enhanced locomotor activity. This is the first report documenting the involvement of brain ERK pathway in mediating an acute behavioral activity as opposed to the role of this cascade in long-term changes in behavior or in neuronal plasticity. Nevertheless, the role of striatal ERK in the present context reflects alterations in intracellular signaling that arise during the development of dopaminergic supersensitivity.
The present study provides evidence that activation of striatal ERK signaling is required for mediating the contralateral rotational behavior that is elicited in response to D 2 dopamine receptor stimulation in unilateral 6-OHDA-lesioned rats. The evidence indicates that striatal neuronal MAPK pathway is essential in D 2 dopamine receptor-mediated regulation of locomotor activity particularly under the condition of dopamine receptor supersensitivity, thus supporting a role for ERK signaling in neuronal plasticity.
